SUTENT is used to treat GIST (gastrointestinal stromal tumor). This is a rare cancer of the stomach, bowel, or esophagus. SUTENT is used when the medicine Gleevec® (imatinib mesylate) did not stop the cancer from growing or when you cannot take Gleevec.
Gleevec is a registered trademark of Novartis AG.

First Resource offers many services to help you access Pfizer medicines. Enrollment
is easy. A simple phone call can start the process. If you need to take a Pfizer
cancer medicine, First Resource offers these services:
 |
- Reimbursement assistance—A First Resource counselor can help you understand
your coverage and reimbursement options. One of the ways the counselor can help
includes benefit verification, in which your counselor will review your insurance
benefits to see how you are covered for the medicine you need
- Alternate funding assistance—First Resource can help you find other sources
of funding (if available) if you need them. You may also be able to receive a temporary
supply of medication from Pfizer while you apply for alternate funding
- Appeals assistance—First Resource helps with the appeals process if your insurance
company underpays a claim or denies coverage. First Resource counselors help monitor
and track the status of each appeal until a decision is made
|
Medicines available through First Resource include SUTENT. For a complete list,
please see
www.PfizerHelpfulAnswers.com.
 |
In order to view PDF documents, you must have Adobe® Reader®
installed on your computer. If you do not have Adobe Reader, download it from the
Adobe Web site.
|
Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is
not responsible for the content or services on that site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated
in the United States and/or other countries.